BioNTech (BNTX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$2.22
- Estimate
- -$2.08
- Surprise
- -6.8%
- Score today
- 4.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
BioNTech (BNTX) reported a wider loss than forecast — diluted EPS of -$2.22 against the -$2.08 estimate (a 6.8% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates BNTX Sell at 4.4/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate; this quarter's -6.8% surprise compares with a -64.8% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Quality below floor (3.4 < 4.0)
- Momentum score 1.4/10 — below 4.5 minimum
- Reward/Risk 1.4:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $97.50
- Price target
- $106.98
- Stop
- $89.96
- Upside to target
- +9.7%
- Reward-to-risk
- 1.4:1
Risk check: RSI 16 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
BNTX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $24.30B
- P/E (fwd)
- -17.0
- 52-week range
- $79.52–$124.00
- Off 52-week high
- 21.4%
- RSI (14)
- 16
- Volume vs avg
- 0.68×
- Score today
- 4.4/10